Connect with us

Breaking News

Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery

[ad_1]

By David Sachs

Merck KGaA said that it has partnered with BenevolentAI and Exscientia on an initiative to discover more drugs with artificial intelligence, which the company says will yield higher success rates.

The German science and technology company said on Wednesday that the partnership with the two U.K. AI firms includes access to an…

[ad_2]

Source link